陳 彩雲

Medicine & Life Sciences

1. ADI PEG20 10%
2. Allogeneic Cells 9%
3. Anaplastic Large-Cell Lymphoma 9%
4. Aplastic Anaemia 22%
5. B-Lymphocytes 16%
6. Blood Platelets 11%
7. Bone Marrow 21%
8. Drug Therapy 29%
9. Epstein-Barr virus encoded RNA 1 23%
10. Hematopoietic Stem Cell Transplantation 10%
11. Hematopoietic Stem Cells 9%
12. Hemophagocytic Lymphohistiocytosis 13%
13. In Situ Hybridization 9%
14. Incidence 14%
15. Leukemia, Myelogenous, Chronic, BCR-ABL Positive 25%
16. Lymphocytes 9%
17. Lymphoma 34%
18. Lymphoma, Large B-Cell, Diffuse 39%
19. Multiple Myeloma 13%
20. Mutation 12%
21. Myelodysplastic Syndromes 15%
22. Myeloid Cells 11%
23. N-(1-4-methoxy-benzenesulfonyl)-2,3-dihydro-1H-indol-7-yl)formamide 23%
24. Nasopharyngeal Neoplasms 12%
25. Natural Killer T-Cells 30%
26. Neoplasms 16%
27. Non-Hodgkin's Lymphoma 16%
28. Paroxysmal Hemoglobinuria 19%
29. Peripheral T-Cell Lymphoma 15%
30. Population 9%
31. Precursor Cell Lymphoblastic Leukemia-Lymphoma 18%
32. ravulizumab 10%
33. Registries 17%
34. Rituximab 10%
35. Safety 14%
36. Skin 11%
37. Stem Cell Transplantation 18%
38. Survival 18%
39. T-Cell Lymphoma 50%
40. Thalidomide 12%
41. Therapeutics 14%
42. Thymoma 11%
43. Tubulin Modulators 15%